Retatrutide vs Tirzepatide: triple agonist vs Mounjaro, head-to-head

Both molecules belong to the same incretin class but activate a different number of receptors. Tirzepatide hits two (GLP-1 + GIP). Retatrutide hits three (GLP-1 + GIP + glucagon). That single extra receptor changes the entire metabolic profile, and the size of the weight loss curve.

GLP-1 and GIP (the two receptors tirzepatide targets) primarily work on appetite and insulin response. They signal satiety to the brain, slow gastric emptying so you feel full longer, and improve glucose disposal. The weight loss is driven almost entirely by eating less. Tirzepatide does not directly change how much energy your body burns at rest.

Retatrutide adds the glucagon receptor. When pulsed chronically through a peptide drug, glucagon activates hepatic fat oxidation, increases basal metabolic rate, and shifts the body toward burning stored fat as fuel even at rest. That mechanism is responsible for the extra 2 to 5 percentage points of weight loss retatrutide shows over tirzepatide at equivalent timepoints.

For a 90kg person, tirzepatide at 15mg produces around 20kg loss over 72 weeks. Retatrutide at 12mg produces around 22kg over 48 weeks in the Phase 2 data. Individual variation is large: responders on either drug can exceed these averages by several percentage points; non-responders plateau earlier.

At the 12-week mark, retatrutide users typically report around 10% body weight loss vs tirzepatide users at around 8%. The gap widens over time because glucagon activation drives continued fat oxidation even after appetite adapts.

Retatrutide has a slightly more intense side effect profile during dose escalation, particularly nausea and appetite reduction in the first 4 to 6 weeks. Tirzepatide is generally better tolerated at equivalent stages because GIP co-agonism buffers some GLP-1 effects.

One of the most common patterns in the Philippines expat community is upgrading from tirzepatide to retatrutide after plateau. Finish your last tirzepatide dose on schedule, wait 7 days, then start retatrutide at 2mg weekly and titrate upward. Do not start at your tirzepatide-equivalent dose. The glucagon activation is a new stressor for your system and the gradual ramp matters.